American Cyanamid

Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

Retrieved on: 
Wednesday, May 1, 2024
Health, Medical Devices, Consumer, Women, Surgery, Health Technology, General Health, Xavier University, FDA, University, ESTA, American Cyanamid, Woman, Regenerative medicine, Breast augmentation, Johnson & Johnson, U.S. FDA, Science, Marketing, MBA, PMA, Organization

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America.
  • “Jeff is the ideal person to introduce Motiva to the United States,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs.
  • Mr. Ehrhardt was most recently General Manager for Plastic Surgery & Regenerative Medicine at Allergan Aesthetics.
  • "Joining Establishment Labs is in many ways the culmination of the last 25 years of my career,” said Jeff Ehrhardt.

SLWM Names Thomas Juhase Chief Executive Officer

Retrieved on: 
Thursday, March 7, 2024
Supply Chain Management, Marketing, Retail, Communications, Digital Marketing, Seton Hall University, American Cyanamid, RRD, IBM, Growth, Bowne & Co., University, Business administration, Donnelley Financial Solutions, Bowne, DFIN, RR Donnelley, Management

SLWM , a leader in tech-enabled marketing activation, recently appointed Thomas Juhase as the organization’s Chief Executive Officer (CEO).

Key Points: 
  • SLWM , a leader in tech-enabled marketing activation, recently appointed Thomas Juhase as the organization’s Chief Executive Officer (CEO).
  • “Tom brings a wealth of experience, fresh perspectives, and a reputation for transformative leadership that makes him the perfect fit to lead SLWM,” said Kevin Sherlock, Executive Chairman.
  • As a founding executive team member and Chief Operating Officer, he was integral in transforming the company from its manufacturing roots into a global software powerhouse.
  • "I am honored to join SLWM as its CEO and excited about the opportunities that lie ahead," added Juhase, newly appointed CEO of SLWM.

1 Day Online Process Validation Guidance Requirements Course: Focus on FDA and EU Annex 15: Qualifications and Validation

Retrieved on: 
Friday, December 15, 2023
Transfer, ICH, Genetics, DNA, GMP, Risk management, Laboratory, Union Carbide, Clinical trial, BD (company), Comparison, Technology transfer, Environmental monitoring, Microbial genetics, Research, Ohio State University, FDA, Constitution, QC, API, Quality control, Requirements engineering, Bacteria, Conference, Development, Learning, Active ingredient, Stage 2, Outline, American Cyanamid, Process validation, Medical device, Nursing, Property management, Fine chemical, Authentication, Microbiology

DUBLIN, Dec. 15, 2023 /PRNewswire/ -- The "Process Validation Guidance Requirements course (FDA and EU Annex 15: Qualifications and Validation) Course" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 15, 2023 /PRNewswire/ -- The "Process Validation Guidance Requirements course (FDA and EU Annex 15: Qualifications and Validation) Course" training has been added to ResearchAndMarkets.com's offering.
  • The experts for FDA Process Validation Training will address these questions in Stage 2 as presented here.
  • Objectives of Learning for FDA Process Validation Training:
    Why are these FDA Guidance/EU Guidelines for Industry-Process Validation so significant to the pharmacological and ergonomics industry?
  • An Outline to Phase 1 Guidance for Industry and Its Application within the "NEW" Process Validation.

Life Biosciences Appoints Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer

Retrieved on: 
Monday, February 13, 2023
Autophagy, Therapy, Biology, Harvard University, Wyeth, Ageing, University, Behavior, Psychiatry, American Cyanamid, Drug discovery, Doctor of Philosophy, Pharmaceutical industry, Nursing, Life, Pfizer

BOSTON, Feb. 13, 2023 /PRNewswire/ -- Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the appointment of Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer. At Life Biosciences, she will be responsible for leading the company's scientific research and development efforts built on the epigenetic reprogramming science of Dr. David Sinclair and the chaperone-mediated autophagy discoveries of Dr. Ana Maria Cuervo.

Key Points: 
  • BOSTON, Feb. 13, 2023 /PRNewswire/ -- Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the appointment of Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer.
  • "Dr. Rosenzweig-Lipson brings great scientific and strategic leadership to Life Biosciences," said Jerry McLaughlin, Chief Executive Officer at Life Biosciences.
  • "I am thrilled to be joining Life Biosciences to revolutionize the treatment of a wide-range of age-related disorders," said Dr. Rosenzweig-Lipson.
  • "I look forward to collaborating with the strong mission-driven team at Life Biosciences and its outstanding scientific collaborators."

Akron Bio Appoints Christopher Murphy as Chief Executive Officer

Retrieved on: 
Monday, December 12, 2022
Biotechnology, Pharmaceutical, Other Manufacturing, Medical Supplies, Health, Genetics, Manufacturing, Other Health, Akron, Ohio, Biotechnology, Regenerative medicine, Arclin, Thermo Fisher Scientific, American Cyanamid, Medicine, Bio, Acquisition, Fine chemical, Pharmaceutical industry, Pfizer

Akron Bio (Akron), a provider of critical inputs for cell and gene therapies, today announced the appointment of Christopher Murphy as Chief Executive Officer.

Key Points: 
  • Akron Bio (Akron), a provider of critical inputs for cell and gene therapies, today announced the appointment of Christopher Murphy as Chief Executive Officer.
  • Mr. Murphy is a biotechnology industry veteran with more than 30 years of experience in advanced therapy and biological drug development and manufacturing.
  • Mr. Murphy joined Thermo Fisher Scientific as part of its acquisition of Brammer Bio, where he served as Chief Operations Officer.
  • Mr. Murphy said, I am incredibly excited to join Akron Bio and partner with innovators to provide high-quality, critical materials and services that power the future of medicine.

Certis Biologicals Elevates Leadership for U.S.-Based Sales Efforts

Retrieved on: 
Monday, November 21, 2022
Agriculture, Natural Resources, Sustainability, Environment, Other Manufacturing, Chemicals, Plastics, Green Technology, Manufacturing, Investment, Marketing, CDMS, Multimedia, Social media, Caterpillar Inc., Biologicals, China Biologic Products, Growth, Natural Resources, Certis Group, American Cyanamid

Certis Biologicals today announced that veteran sales leader Tim Riley has been tapped to helm the companys U.S.-based sales team as National Sales Director for U.S. Ag Business.

Key Points: 
  • Certis Biologicals today announced that veteran sales leader Tim Riley has been tapped to helm the companys U.S.-based sales team as National Sales Director for U.S. Ag Business.
  • View the full release here: https://www.businesswire.com/news/home/20221121005698/en/
    Certis Biologicals today announced that veteran sales leader Tim Riley has been tapped to helm the companys U.S.-based sales team as National Sales Director for U.S. Ag Business.
  • (Photo: Business Wire)
    Riley joined Certis Biologicals in 2020 as Key Account Manager, supporting the companys business partnerships with distribution leaders.
  • As National Sales Director, he will continue those efforts by managing the companys nationwide team of sales managers and key accounts.

Latest Process Validation Guidance Requirements course (FDA and EU Annex 15: Qualifications and Validation) (November 7-8, 2022) - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 3, 2022
FDA, Health, Continuing, Pharmaceutical, Education, Compliance, Chesapeake Biological Laboratory, Quality control, Laboratory, BD (company), QC, Environmental monitoring, Bacteria, History, Union Carbide, Microbial genetics, American Cyanamid, Development, Ohio State University, GMP, Genetics, Medical device, Fine chemical, Microbiology

Industrial and Amenities specialists who need to grow and participate in developing understanding regarding the issues surrounding Method Endorsement.

Key Points: 
  • Industrial and Amenities specialists who need to grow and participate in developing understanding regarding the issues surrounding Method Endorsement.
  • Time of starting the session: 09.30 AM
    What is included in the "New" Process Validation (PV) Guidance?
  • History and Controlling Basis
    What's Included within Phase 1, Stage 2
    How does One Understand and Utilize Them?
  • We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

On National Perseverance Day, Best-Selling Author Sander A. Flaum Releases "Perseverance as a Means to Overcome Your Life's Obstacles"

Retrieved on: 
Tuesday, October 18, 2022
News, Associated, Mindfulness, VP, Stuttering, Love, Sanders, The New York Times, Nose, Leadership, Perseverance, Board, Theatrical scenery, Press, American Cyanamid, Essence, FDA, Ohio State University, Toy, Pharmaceutical industry, Pfizer, Ageing

NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Best-Selling author Sander A. Flaum's latest tome, "Perseverance as a Means to Overcome Your Life's Obstacles," https://amzn.to/3D1fs8K , honors perseverance and recounts his life-long struggle with debilitating stuttering and howwith perseverance and mindfulnesshe transcended his affliction.

Key Points: 
  • NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Best-Selling author Sander A. Flaum's latest tome, "Perseverance as a Means to Overcome Your Life's Obstacles," https://amzn.to/3D1fs8K , honors perseverance and recounts his life-long struggle with debilitating stuttering and howwith perseverance and mindfulnesshe transcended his affliction.
  • He became the former marketing head of Lederle Laboratories (now Pfizer) and introduced six blockbuster brands, each exceeding $2 billion in sales.
  • He founded, and now runs, Flaum Navigators , a brand marketing consultancy with a team that includes the former Associate Commissioner of the FDA.
  • Sander A. Flaum hasbeen profiled in The New York Times, The Wall Street Journaland the Associated Press.He is a shining example of a life well-lived.

SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer

Retrieved on: 
Tuesday, June 28, 2022
Biotechnology, FDA, Other Health, Health, Radiology, Pharmaceutical, Oncology, Health Technology, Medical Devices, Surgery, Clinical Trials, FDA, Schering-Plough, Bluebird bio, Patient, LinkedIn, Survivor, SBIR, NCI, Diffuse intrinsic pontine glioma, HGG, Senior, Freeman, Patient engagement in Canada, Cell death, Growth, Degenerative disease, Company, MTD, American Cyanamid, Pons, Oxidative stress, Brain, Mass flow (life sciences), Series, High-intensity focused ultrasound, Glioblastoma, Coronavirus Scientific Advisory Board (Turkey), University of Maryland School of Medicine, Maryland School, Clinical trial, Index (publishing), Technology, University, Standard of care, Doctor of Philosophy, Neurosurgery, SDT, Temozolomide, Leadership, Safety, Twitter, ALA, MD, Hope, DIPG, GBM, Pharmaceutical industry, Medical imaging, Medicine

SonALAsense is working on two trials to evaluate the therapeutic potential of SONALA-001 SDT for DIPG and rGBM .

Key Points: 
  • SonALAsense is working on two trials to evaluate the therapeutic potential of SONALA-001 SDT for DIPG and rGBM .
  • The DIPG trial is actively recruiting and the rGBM clinical trial will begin recruiting shortly.
  • SDT utilizes SONALA-001 (a drug) in combination with MR-guided focused ultrasound (a device) to selectively target and kill tumor cells.
  • Follow SonALAsense on Twitter and LinkedIn and visit our website: https://sonalasense.com/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005315/en/

Forge Biologics Forms Independent Scientific and Manufacturing Advisory Board with Panel of Gene Therapy Leaders

Retrieved on: 
Tuesday, May 17, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Department, Senior, Product, Company, Associate professor, Voyager, Drug discovery, Multimedia, Patient, Goal, Lung, GLP, Therapy, Lists of diseases, Blood, University of Texas Southwestern Medical Center, Science Translational Medicine, CGMP, University College London, Cell biology, Laboratory, Research, National Heart, Lung, and Blood Institute, American Cyanamid, Nervous system, Gene, Virology, AAV, University, Production, National, Entrepreneurship, CEO, Pharmaceutical industry, Vaccine, Management, Hearth, Science, Forge

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today the formation of an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development.

Key Points: 
  • Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today the formation of an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development.
  • The board will serve the traditional functions of a scientific advisory board, with a distinct and strategic emphasis on manufacturing advancements.
  • Dr. Kotin is a preeminent expert in AAV gene therapy manufacturing and the co-inventor of the baculovirus-based AAV production system.
  • Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company.